Christopher Lau
Pulmonary Disease · Weston, FLNPI 1255642831
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $153 and has fallen 65.2% since, to $53 in 2025. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 16 payments — averaging $29.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$77
- Actelion Pharmaceuticals US, Inc.$67
- Pulmonx Corporation$67
- Resmed Corp$57
- Boehringer Ingelheim$42
- Insmed, Inc.$38
- plus $123 from 5 others
Across 6 payments — averaging $14,833 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson$89K
What the payments were for
- Food & beverage$45296%
- Education$184%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 3 | $77 |
| Actelion Pharmaceuticals US, Inc. | 2 | $67 |
| Pulmonx Corporation | 1 | $67 |
| Resmed Corp | 1 | $57 |
| Boehringer Ingelheim | 2 | $42 |
| Insmed, Inc. | 2 | $38 |
| AstraZeneca | 1 | $36 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Baxter Healthcare | 1 | $26 |
| Bayer | 1 | $18 |
| Philips North America LLC | 1 | $16 |
How this compares
$470 in reported general payments places this provider in the 20th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 18 | $444,878 |
| OpsumitMacitentan | 12 | $151,624 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $57,773 |
| Dupixent SyringeDupilumab | 12 | $45,876 |
| Ambrisentan | 14 | $42,750 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 71 | $38,314 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $32,329 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 62 | $31,230 |
| Spiriva RespimatTiotropium Bromide | 36 | $24,690 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $11,037 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $9,631 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 54 | $8,779 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $8,634 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $8,048 |
| Arnuity ElliptaFluticasone Furoate | 22 | $6,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $67 | $151,62412 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $42 | $55,92098 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $36 | $20,66855 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Weston
- Franck RahaghiWeston$1.2M
- Anas HadehWeston$800K
- David ZismanWeston$112K
- Roger AlvarezWeston$82K
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.